ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2013
Normalization of mass cytometry data with bead standards.
Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 482 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
482 citing papers in PubMed, 791 citations in OpenAlex.
- Trial
- Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.Nature communications · 2024Trial
- Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.Nature medicine · 2024Trial
- Activated sputum eosinophils associated with exacerbations in children on mepolizumab.The Journal of allergy and clinical immunology · 2024Trial
- The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.Nature communications · 2026Article
- Mass Cytometry Reveals Cell Type-specific Immune Remodeling in Placentas of Women with Chronic Hepatitis B Infection.Journal of clinical and translational hepatology · 2026Article
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- CD9Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Quantitative Single-Cell Multielemental Analysis Using Metal-Loaded Microparticles: toward a Universal Quantification Workflow in Mass Cytometry.Analytical chemistry · 2026Article
- Immunological maladaptation preceding spontaneous preterm birth in human pregnancies.Nature communications · 2026Article
- NLRC5 Deficiency Delays Bone Healing by Inhibiting Osteogenic Differentiation of Bone Marrow-Derived Stem Cells and Altering the Immune Microenvironment.International journal of molecular sciences · 2026Article
- Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Critical illness expands a transcriptionally distinct hypometabolic CD8bioRxiv : the preprint server for biology · 2026Article
- Macrophage-derived fibronectin suppresses antitumor immunity via tissue stiffening and immunosuppressive cell induction in cancer mouse models.Nature communications · 2026Article
- A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome.Nature communications · 2026Article
- Systematic multi-omic deconvolution of the clinical heterogeneity of Down syndrome.Nature communications · 2026Article
- Navigating the Landscape of Cytometry-Based Single-Cell Proteomics: Quantification, Annotation, and Resources.International journal of molecular sciences · 2026Review
- Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity.bioRxiv : the preprint server for biology · 2026Article
- Article
422 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Mass cytometry uses atomic mass spectrometry combined with isotopically pure reporter elements to currently measure as many as 40 parameters per single cell. As with any quantitative technology, there is a fundamental need for quality assurance and normalization protocols. In the case of mass cytometry, the signal variation over time due to changes in instrument performance combined with intervals between scheduled maintenance must be accounted for and then normalized. Here, samples were mixed with polystyrene beads embedded with metal lanthanides, allowing monitoring of mass cytometry instrument performance over multiple days of data acquisition. The protocol described here includes simultaneous measurements of beads and cells on the mass cytometer, subsequent extraction of the bead-based signature, and the application of an algorithm enabling correction of both short- and long-term signal fluctuations. The variation in the intensity of the beads that remains after normalization may also be used to determine data quality. Application of the algorithm to a one-month longitudinal analysis of a human peripheral blood sample reduced the range of median signal fluctuation from 4.9-fold to 1.3-fold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.